Kinnate Biopharma Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 112.65 million compared to USD 116.27 million a year ago. Basic loss per share from continuing operations was USD 2.42 compared to USD 2.64 a year ago.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.65 USD | -0.38% | -.--% | +11.81% |
Apr. 03 | Kinnate Biopharma Inc. Announces Board Resignations | CI |
Apr. 03 | Kinnate Biopharma Inc.(NasdaqGS:KNTE) dropped from NASDAQ Composite Index | CI |
1st Jan change | Capi. | |
---|---|---|
+11.81% | 125M | |
+23.37% | 47.02B | |
+49.56% | 41.86B | |
-0.94% | 41.76B | |
-4.32% | 28.8B | |
+11.29% | 26.05B | |
-20.92% | 19.15B | |
+3.20% | 12.55B | |
-2.67% | 11.82B | |
+30.23% | 12.34B |
- Stock Market
- Equities
- KNTE Stock
- News Kinnate Biopharma Inc.
- Kinnate Biopharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2023